Alumis To Unveil Phase 3 ONWARD Topline Data For Envudeucitinib In Plaque Psoriasis; Stock Up

Alumis (ALMS) said it will report topline results from the Phase 3 ONWARD program for its oral TYK2 inhibitor envudeucitinib (ESK-001) in moderate-to-severe plaque psoriasis on January 6, 2025, with a conference call at 8:00 a.m. ET. The ONWARD program comprises two 24-week randomized, double-blind, placebo-controlled global trials (ONWARD1 and ONWARD2) and an ongoing optional long-term extension (ONWARD3); the company previously reported positive 52-week open-label extension (STRIDE) phase 2 data showing sustained/increasing PASI90/PASI100 and sPGA0 at 40 mg twice daily. The announcement drove a sharp intraday move—shares jumped ~32.5% to $11.27 after the overnight release—making this a material, company-specific catalyst for ALMS investors while broader market impact is limited.

Analysis

Market structure: The immediate beneficiary is ALMS (ticker ALMS) and vendors/CROs tied to oral TYK2 programs; a positive ONWARD readout would threaten share and pricing power of IL‑17/IL‑23 injectable incumbents (e.g., ABBV, NVS, JNJ) over 12–36 months if oral efficacy approaches PASI90/PASI100. The 32% premarket gap shows demand is front‑loaded into a binary Jan 6, 2025 event; supply (shares and options) will be tight and implied volatility will spike around the datapoint.

Risk assessment: Tail risks include a safety signal (class JAK/TYK2 cardiovascular/hematologic concerns), manufacturing or disclosure issues, or a failed primary endpoint — each could erase >50% of market cap. Near term (days) view is event‑driven; short term (weeks) is volatility decay and secondary analyses; long term (quarters) depends on regulatory pathway and payer willingness to substitute biologics (2026–2028 commercialization window).

Trade implications: Tactical plays: small, defined‑risk exposure to ALMS pre‑data and a longer dated directional LEAP if results are clean. Use options to control downside: buy ATM straddle or buy‑call/spread into Jan 2026 to capture upside while capping loss. Rotate 1–3% of immunology allocation from large biologic incumbents (ABBV/NVS/JNJ) into oral‑immunology names and suppliers.

Contrarian angles: The 32% move likely overprices a clean readout; implied vols will be rich — sell premium post‑print if positive. Historical parallels: small‑cap drug readouts often reverse 30–70% on mixed safety/label outcomes. Payer pushback and narrow labels could cap upside even with positive efficacy, so treat Jan 6 as a de‑risked entry point rather than a free call.

Key Decisions for Investors

• Establish a limited long position in ALMS equal to 1–2% of portfolio risk capital ahead of Jan 6, 2025 topline, sizing to tolerate a 50% downside; exit or trim into strength within 3 trading days post‑release.
• Buy an event straddle on ALMS with expiration the week of Jan 17, 2025 (ATM calls and puts) sized to 0.5–1% of portfolio to capture the expected IV spike, then close both legs within 48–72 hours after the print to avoid IV crush.
• If bullish on long term commercialization, buy a Jan 17, 2026 call spread (buy $10 calls / sell $25 calls) allocating 1–2% to capture upside while capping premium outlay; reassess after FDA/phase‑3 complete safety readouts.
• Reduce relative exposure to IL‑17/IL‑23 biologic incumbents (ABBV, NVS, JNJ) by 1–2% and reallocate into oral immunology/supply‑chain names over the next 3–12 months to position for potential pricing pressure; monitor payer guidance over 60–180 days.
• Predefine trading thresholds: if ALMS > $18 within 10 trading days post‑data, trim long exposure to 0.5% (take profits); if ALMS < $6 after the print, add up to 3–5% as a distressed, high‑conviction buy, contingent on no major safety signal and stable cash runway.